M&A / Deals AZ forges ever-closer ties with China’s CSPC Pharma PharmaphorumAstraZeneca has returned to China's CSPC Pharma to fill its R D pipeline, reaching a new $1.77bn agreement to develop drugs for kidney diseases.Read full story pharminent July 2, 2026 (Last updated: July 3, 2026) Pharmaphorum AstraZeneca has returned to China’s CSPC Pharma to fill its R D pipeline, reaching a new $1.77bn agreement to develop drugs for kidney diseases. Read full story Post navigation Previous: Roche’s KRAS drug tops its rivals in lung cancer trialNext: Novartis receives European Commission approval for Itvisma for spinal muscular atrophy Related Stories M&A / Deals Exegenesis Bio and Modalis sign research deal for Duchenne therapy pharminent September 11, 2026 M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026